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Objective: To compare the outcomes of dogs treated for single extrahepatic congenital 25 
portosystemic shunts (CPSS) by thin film banding (TFB) or placement of an ameroid 26 
constrictor (AC) at a single institution. 27 
Study design: Retrospective case series. 28 
Animals: 76 client owned dogs with CPSS treated with TFB (n=53) or AC (n=23). 29 
Methods: Records were reviewed for signalment, pre-, intra- and postoperative management 30 
and short-term outcomes. Data on second surgeries were reviewed. Long-term outcomes 31 
were obtained by use of an owner-directed health related quality of life questionnaire. The 32 
rates of complications, mortality, and revision surgery were compared between the treatment 33 
groups. 34 
Results: Postoperative complications occurred in 15 dogs with TFB (28%) (9% mortality, 35 
n=5) and 8 with AC (35%) (4% mortality, n=1) dogs. Long-term follow up was available in 36 
41/56 dogs at a median of 53 (15-88) months. Revision surgery for persistent shunting was 37 
performed in 14 (29%) dogs treated initially with TFB, and no dogs treated initially with AC 38 
(P=0.007). Median long-term outcome scores were good in both groups. 9/14 revision 39 
surgeries led to favorable outcomes. 40 
Conclusions: Persistent shunting requiring revision surgery was more common when CPSS 41 
were treated with TFB than AC but both treatments achieved favorable long-term outcomes. 42 
Clinical significance: Treatment of CPPS by placement of an AC rather than a TFB seems 43 





Surgery is currently accepted as the preferred treatment for single extrahepatic congenital 47 
portosystemic shunts (CPSS) in dogs. 1,2 Acute complete ligation of the shunting vessel is not 48 
tolerated in as many as 84% of animals.3 In order to limit the development of life-threatening 49 
portal hypertension and allow complete closure of the shunt without the need for a repeat 50 
surgery, several methods for gradual attenuation have been described. The most commonly 51 
used techniques for extrahepatic CPSS attenuation are the application of an ameroid 52 
constrictor (AC) or a thin film band (TFB), with variable results reported. 4-9 It is 53 
hypothesized that TFB incites an inflammatory reaction and fibrosis of the vessel it is placed 54 
around, resulting in complete occlusion of the CPSS in 63-65% of dogs. 6,9 However, the 55 
stark variations in chemical and ultrastructural composition of the TFB used in practice in 56 
addition to the lack of standardization of the TFB placement have raised concerns over the 57 
repeatability and reliability of TFB use for shunt attenuation.10 The casein ring of the AC 58 
expands to some degree after implantation, resulting in luminal compression of the vessel 59 
along with initiating inflammation and thrombosis, eventually causing vessel occlusion. 11-14 60 
It was demonstrated by recent studies that AC closure mechanism was likely involving 61 
calcium-mediated inter-protein interactions rather than the imbibition of water only.15,16 62 
Complete shunt occlusion is achieved in 79-82% of dogs with this technique. 5,17  63 
Persistence and recurrence of clinical signs is the most common complication of CPSS 64 
surgery and is reportedly due to incomplete vessel occlusion with persistent residual shunting 65 
(TFB – 16-47%, AC – 18-21%), suboptimal placement of the attenuating device (TFB – 15-66 
40%) or development of additional acquired shunts (TFB – 19%, AC – 4%). 5,6,9,18-20 The 67 
evidence directly comparing these techniques is currently limited and assessments of 68 
recovery to a ‘normal’ quality of life are lacking.2 In a recent multi-institutional study it was 69 
concluded that the AC provided more predictable vessel occlusion than the TFB based on 70 
 
 
abdominal ultrasound and a previously established clinical outcome grading score. 4,19 In the 71 
attempt to better assess long-term recovery after CPSS surgery, the development of a health-72 
related outcome scoring system (CPSS score) alongside owner-assessed quality of life are 73 
described in a recent publication where dogs after CPSS surgery are compared to a healthy 74 
control population. 21 It was demonstrated in that study that there are discrepancies between 75 
quality of life assessed by the owner and CPSS scores. A significant difference was 76 
demonstrated between the CPSS score of normal dogs and of dogs after CPSS surgery. 21  77 
The objective of this study was to compare the outcomes of dogs treated for single 78 
extrahepatic congenital portosystemic shunts (CPSS) by thin film banding (TFB) or 79 
placement of an ameroid constrictor (AC) at a single institution. The main aim was 80 
specifically to more accurately evaluate the long-term response to surgery by using a recently 81 
published health related quality of life score and to report the frequency, reasons for and 82 




Materials and methods 85 
Study population 86 
This study was approved by the University of Bristol Animal Welfare and Ethical review 87 
Body (AWERB) (VIN/16/046) and the University of Bristol Research Ethics Committee 88 
(FREC). 89 
Descriptive data were gathered solely from the medical records of dogs that underwent 90 
diagnosis of and surgical treatment for extrahepatic CPSS from 2009 to 2016 at the Bristol 91 
Veterinary School Small Animal Hospital. Long-term follow up was obtained via owner 92 
questionnaire, as detailed below. 93 
 94 
Medical records review 95 
Records were reviewed for signalment, method of CPSS diagnosis, results of pre-operative 96 
serum fasting and postprandial bile acid concentrations, pre-operative medical management, 97 
shunt morphology, type of surgery performed, use of portovenography and / or portal 98 
pressure measurement, additional surgical procedures performed, duration of surgery, 99 
postoperative complications, duration of hospitalization, clinical outcome and requirement 100 
for a second surgical intervention. The subjective response to medical management pre-101 
surgery was graded as follows: good = resolution of clinical signs, moderate = improvement 102 
in clinical signs, poor = no improvement in clinical signs or relapse.22 Intraoperative 103 
complications were defined as an adverse surgical event that required surgical or therapeutic 104 
(pharmacological) intervention to correct. Postoperative complications were defined as an 105 
adverse event occurring before hospital discharge.22 Postoperative mortality was defined as 106 
death or euthanasia within 30 days of surgery. Dogs in which partial or complete suture 107 




Follow up 110 
Short-term (< 6 months) outcome information was recorded from the animal’s medical record 111 
as per conversations with the referring veterinarian and/or the owner or from re-examination 112 
notes. Where available, postoperative serum fasting and postprandial bile acid concentrations 113 
were recorded and values outside the reference range were reported. Outcome was graded as 114 
previously described as: excellent = clinically normal dogs that were not receiving any 115 
medical treatment for hepatic encephalopathy or a prescription diet, good = clinically normal 116 
dogs receiving medical treatment for hepatic encephalopathy and / or a prescription diet, poor 117 
= dogs with clinical signs of CPSS or dogs that died or were euthanatized because of CPSS. 4 118 
For dogs that required repeat surgery the following data were collected: type of primary 119 
surgery performed, reasons that influenced the decision to perform revision surgery, type of 120 
revision surgery, time from initial to revision surgery and outcome. 121 
Long-term (>12 months) outcome information was obtained by use of an online owner-122 
directed health related quality of life (HRQoL) questionnaire, which has recently been 123 
reported, additionally to being graded as above. 21 Owners were contacted to participate via 124 
telephone, email or regular mail. 125 
 126 
CPSS Score 127 
The frequency and severity of clinical signs were used to calculate a CPSS score as 128 
previously described (supplementary material). 21 Frequency of each clinical sign was 129 
recorded on a five-point categorical scale as: never, less than once a month, monthly, weekly, 130 
daily. Clinical signs were divided into three classes according to severity, with class 1 being 131 
multiplied by 3, class 2 by 2 and class 3 by 1. For presence of confirmed urolithiasis or 132 
urethral obstruction, an additional 2 points were added. For retarded growth an additional 4 133 
points were added if it was present, 2 if the answer was unsure and 0 for not present. This 134 
 
 
CPSS score represents a global, semi-objective, score of the dog’s HRQoL. Greater CPSS 135 
scores represent a more severely affected dog, with the highest achievable score being 110. In 136 
addition, owners were asked to rate their dog’s overall subjective quality of life (QoL) at the 137 
time of last follow up on a visual analog scale from ‘Worst imaginable’ through to ‘Best 138 
imaginable’. This gave an owner-perceived QoL score out of 100. 139 
 140 
Statistical analysis 141 
Statistical analysis was performed using a statistical software package (SPSS Statistics 24.0.0 142 
IBM, Woking, UK).  Data was assessed graphically for normality. Median and range were 143 
reported for skewed data. Categorical data were reported as percentages. The complication 144 
rate, mortality and the proportion of dogs needing revision surgery were compared between 145 
the TFB and AC groups with the Chi-squared or Fisher’s Exact tests as appropriate. 146 





Study population – Seventy-six dogs met the inclusion criteria. Fifty-three dogs (70%) were 150 
treated by thin film band placement and 23 (30%) by placement of an ameroid constrictor.  151 
The median age was 14 months (range 4-96 months). 152 
Preoperative data – Diagnosis of an extrahepatic CPSS was made on the basis of clinical 153 
signs, hematology, serum biochemistry, bile acid stimulation testing, ammonia and diagnostic 154 
imaging. Medical treatment was administered for a median of four weeks (range 1-52 weeks) 155 
and consisted of: a combination of a prescription diet, lactulose and antimicrobials in 67 dogs 156 
(89%), a combination of lactulose and antimicrobials in six dogs (8%) and solely 157 
antimicrobials in one dog (1%). Medical management data were unavailable for one dog and 158 
one dog did not receive any medical treatment. Response to medical management was 159 
recorded in 67 dogs as good (n=16, 24%), moderate (n=47, 70%) and poor (n=4, 6%). 160 
Information on the response to medical management was not recorded in the medical files of 161 
seven dogs. Serum bile acid concentrations (SBA) were measured immediately before 162 
surgery as follows: fasting SBA in 64 dogs with a median value of 93.2 μmol/L (range 3-163 
387.3μmol/L; reference interval 0-15μmol/L), postprandial SBA in 51 dogs with a median 164 
value of 191.4 μmol/L (range 32.8-747μmol/L; reference interval 0-25μmol/L). Pre-operative 165 
imaging diagnosis was made by computed tomography angiography (CTA) in 30 dogs and 166 
abdominal ultrasound in 45 dogs. Diagnostic imaging was not recorded in the medical file of 167 
one dog. 168 
First surgery – The type of surgical treatment was selected at the discretion of the surgeon 169 
and was therefore not standardized. Median surgery time was 85 (range 45-150) minutes in 170 
the TFB group and 77.5 (range 20-100) minutes in the AC group. Intraoperative 171 
portovenography and / or portal manometry were performed at surgeon discretion. Dogs 172 
treated with TFB received a partial attenuation to a degree that was considered safe by 173 
 
 
objective (portal manometry) and / or subjective assessment of portal hypertension 174 
intraoperatively. The TFB (Grade MS350, Cello Paper, Fairfield, NSW, Australia) was 175 
secured with metallic clips. 18 Additional procedures (cystotomy, ovariectomy, castration) 176 
were performed at the discretion of the surgeon and client and were performed in 22 dogs 177 
(42%) and 9 dogs (39%) in the TFB and AC group respectively. 178 
Dogs were hospitalized postoperatively for a median of four (range 3-10 days) and five days 179 
(range 3-11 days) in the TFB and AC group respectively. 180 
Complications – Complications occurred in 15 dogs (28%) in the TFB group. Intraoperative 181 
complications included: intraoperative haemorrhage after laceration of a mesenteric vessel 182 
(1), intraoperative hypotension prompting fresh frozen plasma administration (n=1). 183 
Immediate postoperative complications included: ascites (n=2), post-operative hemorrhage 184 
(n=2) with blood transfusion required (n=1), pancreatitis (n=2) with jugular vein thrombosis 185 
(n=1), hypoglycaemia (n=1). Post attenuation neurological signs (PANS) developed in six 186 
dogs (seizures (n=5), ataxia/ head pressing that resolved in 48h (n=1)). Seizures leading to 187 
death or euthanasia developed in four dogs (8%) two to seven days postoperatively. In the 188 
remaining dog who developed postoperative seizures and survived the postoperative period, 189 
the seizures were judged to be non-shunt related, as the shunt was attenuated based on CT 190 
with concurrent normalization of bile acids. One dog died four weeks postoperatively after an 191 
episode of vomiting and dyspnea, despite a good recovery postoperatively. The owner of that 192 
dog reported death of one of the littermates following similar signs due to a congenital 193 
cardiac problem (suspected by the treating veterinarian). The TFB group had an overall 194 
postoperative mortality of 9% (n=5). 195 
In the AC group, complications occurred in eight dogs (35%). One dog developed 196 
intraoperative hypotension with subsequent postoperative portal hypertension that prompted 197 
revision surgery on the following day to replace the AC with a TFB (Figure 1). Immediate 198 
 
 
postoperative complications included: anorexia that required placement of a feeding tube 199 
(n=2), PANS (generalized seizures, n=3), pancreatitis with ascites (n=1) and persistent 200 
regurgitation (n=1). The dog that developed persistent regurgitation was later diagnosed with 201 
an oesophageal stricture. One dog in this group (4%) was euthanatized due to seizures three 202 
days postoperatively. There was no significant difference in postoperative complications 203 
(P=0.572) or mortality (P=0.661) between the two groups. 204 
Short-term follow up 205 
TFB group – Short-term follow up was available for 47/49 dogs that survived surgery 206 
(including the dog that had been originally treated with an AC but was revised to a TFB the 207 
following day, Figure 1). Six dogs (13%) were graded as excellent, 31 (66%) as good and 10 208 
(20%) as poor on follow up. Median time of subjective follow up was three months (range 1-209 
6 months). Postprandial SBA were abnormal in 26/37 (70%) of dogs while only 47% (17/36) 210 
of fasted samples were abnormal. Median time of postoperative bile acid testing was 8.5 211 
weeks (range 4-24 weeks).  212 
AC group – Short-term follow up was available for 17/21 dogs that survived surgery 213 
(excluding the dog that had their AC removed and replaced with a TFB the following day). 214 
One dog (6%) was graded as excellent, 13 (76%) as good and three (18%) as poor on follow 215 
up of a median time of two months (range 1-6 months). In this group, postprandial SBA were 216 
abnormal in 9/14 (64%) of dogs while 25% (3/12) of fasted samples were abnormal. Median 217 
time of postoperative bile acid testing was eight weeks (range 4-16 weeks). 218 
Revision surgery for persistent shunting 219 
Fifteen of 49 dogs (31%) that had a TFB placed were identified to have persistent shunting 220 
on diagnostic imaging (CT (n=7), ultrasound (n=6), portovenography (n=2)) in a median time 221 
of 5 months (range 2-54 months) postoperatively. Fourteen of these 49 dogs (29%) had 222 
revision surgery in a median time of six months (range 3-64 months) after the initial 223 
 
 
operation (Table 1). One of the 14 dogs (dog 11; Table 1) had two revision surgeries. TFB 224 
surgery was revised by placing an AC due to persistent shunting; this surgery was later 225 
revised to fully ligate the shunt. Two of the 14 dogs made a good recovery from initial 226 
surgery, with normalization of their bile acids. However, they experienced recurrence of 227 
clinical signs at 3- and 5-years post-surgery, raising the suspicion of shunt recanalization. 228 
None of the dogs that had an AC placed at their initial surgery had a revision surgery 229 
performed. There was a statistically significant difference between the rate of revision 230 
surgeries performed between the two groups (P=0.007). 231 
Long-term follow up 232 
This information was available for 41/56 dogs (73%) that did not undergo revision surgery 233 
(26 TFB and 15 AC) and is presented in Table 2, including mortality. Outcomes of dogs who 234 
underwent revision procedures were available for 12/14 dogs (86%) and these are detailed in 235 
Table 1. Health-related quality of life questionnaires were returned for 27 dogs. Comparison 236 
of subjective owner-perceived quality of life with scores of different outcome grading 237 
methods was available for 51% of dogs and is presented in Table 3. Discrepancy between 238 
outcome grade, CPSS score and owner-reported quality of life is evident with owners 239 




Although a variety of techniques have been reported for the attenuation of extrahepatic 242 
CPSS, the evidence base for recommending one treatment over another is weak, with few 243 
studies comparing one or more treatments.2 Although several previous studies have 244 
compared AC with suture ligation23-25, only one has directly compared AC with TFB.19 245 
We directly compared the short and long-term outcome of AC and TFB using a health 246 
related quality of life questionnaire, which has not been used in dogs treated with gradual 247 
attenuation devices. We also focused on revision surgeries due to persistent shunting.  248 
 249 
We found a high rate of persistent shunting in dogs treated with TFB, with 15/49 250 
surviving dogs (31%) affected and 14 (29%) of these having a revision surgery. This is in 251 
agreement with previous studies that report continued shunting / incomplete shunt closure 252 
rates of 18-47%. 6,9,19 Persistent shunting can result from failure to completely attenuate 253 
the shunt, the development of multiple acquired shunts (MAS), sub-optimal location of 254 
attenuation or uncommonly due to failure to identify a second CPSS. 6,20 The marked rate 255 
of persistent shunting with TFB may relate to inconsistency of the material used, as well 256 
as sterilization and handling methods and potential inconsistency in the amount of 257 
compression of the vessel during placement. 7,10,26 The material of the TFB used in our 258 
study was consistent throughout the study period and qualified as consistent with 259 
cellophane on  biochemical and ultrastructural analysis, thereby eliminating the variable 260 
of TFB inconsistency. 10 Suboptimal device placement (40% rate reported in one study) 261 
may have also been a possible reason for development of persistent shunting in our and 262 
other studies. 6,18,19 Inconsistency in reporting procedural details in the patient records 263 
 
 
may have resulted in missing differences in the level of attenuation provided by TFB 264 
placement. We found a much lower rate of persistent shunting in dogs initially treated 265 
with AC, with no dogs having revision surgery. One dog, initially treated with a TFB had 266 
revision surgery with an ameroid constrictor and subsequently had a further revision 267 
surgery due to persistent shunting. On long-term follow up one additional dog in the AC 268 
group was euthanatized at an unknown time due to signs attributed to CPSS, potentially 269 
increasing the continued shunting rate in the AC group. These findings suggest that the 270 
rate of persistent shunting is lower for dogs treated with AC compared with TFB, which 271 
agrees with the study by Traverson et al. which documented a persistent shunting rate of 272 
13.6% for TFB and 0% for AC.19 This is an important finding, as it may influence 273 
clinical practice and therefore it is noteworthy that the two studies have reached the same 274 
conclusion. The median outcome time in that previous study was 36 months, compared to 275 
55 months in our study.19 The longer follow-up in our study may have allowed us to 276 
identify more long-term persistent shunting associated with TFB compared with the 277 
previous report. Long-term persistent shunting was evident in two dogs in our study that 278 
had suspected shunt recanalization three- and five years postoperatively. Our low rate of 279 
persistent shunting in AC dogs should be interpreted with some caution. Continued 280 
shunting rates of up to 24% are reported for AC and subclinical undetected persistent 281 
shunting may have been possible in this group in our study. 5 Our sample size for the AC 282 
group is considerably smaller than in this previous study, and therefore may be less 283 
representative of the population as a whole. The large difference in persistent shunting 284 
detected in the TFB group may also have been due to the nature of our study 285 
(retrospective, multiple surgeons involved). The nature of the study may further have 286 
 
 
made it possible that the TFB group was followed up more rigorously (i.e. to have more 287 
follow up blood tests or that abnormal blood tests prompted further investigations/ 288 
surgery in some dogs more than others), although this is unproven. Additionally, not all 289 
dogs were postoperatively evaluated for persistent shunting using a standardized protocol 290 
which may have resulted in an underestimation of persistent shunting rates in both 291 
groups. With no revisions in the AC group, the likelihood of incorrect attenuation device 292 
placement is lower, which suggests that the TFB is not working as effectively as the AC 293 
and therefore is failing to completely attenuate the shunt or attenuating it too rapidly and 294 
thereby leading to MAS, although MAS was not diagnosed in the dogs that had revisions 295 
in the current study. The apparent better predictability of shunt closure with AC 296 
compared to TFB in our population also reflects the findings of two studies reporting a 297 
much higher material consistency in chemical and ultrastructural analysis of AC 298 
compared to TFB. 10,15  299 
 300 
We found the postoperative complication rates for both groups comparable (28% for TFB 301 
vs. 35% for AC). These rates are higher than those previously reported for these 302 
occlusion methods individually (9-13% reported for TFB and 10-20% for AC),4,5,11,14,18,26 303 
but close to the rates reported in a recent study comparing TFB (26%) and AC (23%). 19 304 
There is inconsistency in the reporting of complication types in past CPSS studies and 305 
this could have affected the differences in complication rates. Mortality rates were higher 306 
for the TFB group (9% vs. 4% for AC) but overall these were comparable to other studies 307 
(0-9% reported for TFB and 0-14% for AC).4,5,14,17-19,26 Post-attenuation neurological 308 
signs were the main cause of mortality in our study as generalized seizures were the 309 
 
 
cause of death or euthanasia in most dogs (5/6; 83%). This is higher than previously 310 
reported in other studies (0-67%), although the rate of mortality related to non-311 
neurological causes (anaesthetic or surgery related) was therefore much lower.  312 
4,8,9,14,18,19,26-28 However, seizures were the only cause of shunt-related mortality in our 313 
study. 314 
 315 
At long-term follow-up, Dog 7 and Dog 13 (Table 1) were both experiencing intermittent 316 
neurological episodes which may have been due to primary portal vein hypoplasia 317 
(PVH)/ microvascular dysplasia, and/ or the development of MAS. Portal vein hypoplasia 318 
could similarly be responsible for the similar rate of “poor” long-term outcome in both 319 
groups, as could the development of MAS or persistent shunting through the original 320 
shunt, even though the outcome grade may not be representative of the dog’s true clinical 321 
status. While separate hepatic pathology or persistent shunting/ MAS could have been 322 
responsible for this high rate, in comparison with previous reports (0-8%) this still 323 
remains a high number. 5,19 This may, in part, be related to the retrospective nature of all 324 
of the reports and inaccuracy of the outcome grading systems used. The longer median 325 
follow up times in our study may have again contributed to this finding. 326 
 327 
The baseline clinical outcome grading used in our report is a scheme initially described in 328 
a paper by Mehl at al. that was later adapted by several other studies. 4,5,19,29 This grading 329 
scheme is imperfect and has the potential to assign individual dogs negative outcomes 330 
even though their clinical signs are subjectively mild and rare in occurrence or may even 331 
not be directly related to the CPSS. For example, a dog who is free of medical and dietary 332 
 
 
management but experiences a monthly, or less frequent neurological episode (e.g. head 333 
pressing, circling or similar) or an episode of vomiting or lethargy is automatically 334 
assigned a ‘poor’ outcome. The quality of life of such a dog may however be relatively 335 
good. Also, short-term grading in our report was obtained at time-points when 336 
recommendations for weaning off medication and/ or diet were made. Therefore, a true 337 
representation of grades may not have been achieved and interpretation of these outcomes 338 
with caution is warranted. For these reasons, a grading scheme has been developed 339 
(CPSS score) based on a health-related quality of life questionnaire, in an attempt to 340 
refine outcome assessment. 21 That study found that long-term CPSS score remained 341 
increased above that of normal dogs, even when owner assessed quality of life was 342 
excellent, as demonstrated in our study (Table 3).  343 
 344 
Overall, the greater perioperative mortality and higher reoperation rate for the TFB group 345 
suggest that, in this cohort, AC achieved a better overall outcome in the short term and 346 
seems to be the safer of the two methods, confirming and developing further the results of 347 
a recent study. 19 In the current study, revision surgery resulted in ultimate acceptable to 348 
excellent short- or long-term outcomes in 8/12 dogs (67%) based on the CPSS score 349 
(Table 1).  Indeed, it was previously shown that elective staged suture ligation can result 350 
in good outcomes for dogs with extrahepatic CPSS. 27,30,31 However, TFB and AC are 351 
designed to avoid a second surgery and therefore the high rate of revision in the TFB 352 
group is a cause for concern in this cohort. In a recent article six revision surgeries for 353 
nine cases of suspected continued shunting after TFB were reported, however clinical 354 
outcomes for these dogs were not reported individually. 19 Outcomes for dogs that 355 
 
 
underwent revision surgeries were reported separately, as those underwent a variety of 356 
revision procedures (Table 1). 357 
 358 
The study has several limitations related mainly to its retrospective nature. These include 359 
a wide variability in follow-up times, reliance on the accuracy and completeness of 360 
medical records and owner perceptions and bias, involvement of multiple clinicians in 361 
case management and differences in the size of the two populations compared. The 362 
persistent shunting rates in both groups should be interpreted with some caution, as not 363 
all dogs were routinely screened for successful CPSS attenuation by imaging. Therefore, 364 
persistent shunting rates for both groups, could be artificially low. Also, some dogs had 365 
more than two surgeries which made grouping difficult. 366 
 367 
Although we identified a high rate of persistent shunting in the TFB group we are not 368 
able to definitively state whether all of the remaining dogs had complete cessation of 369 
shunting. It remains unclear whether the goal of shunt attenuation is to obliterate shunting 370 
in all dogs or simply resolve clinical signs and provide the dog with a good quality of life 371 
(with some degree of shunting acceptable). It was recently shown that persistent mild 372 
increases in pre- and post-prandial bile acids exist despite resolution of clinical signs in 373 
dogs treated for extrahepatic CPSS.32 However, a relatively large proportion of dogs in 374 
the TFB group in our study required revision surgery and this would be considered a 375 
failure of the initial surgery. The requirement for routine biochemical follow-up and 376 
further surgical intervention in dogs with an apparently good outcome but evidence of 377 
persistent shunting remains unclear.  In our study routine follow-up imaging was 378 
 
 
uncommon. However, dogs with clinical signs attributable to CPSS and increased serum 379 
bile acids had further imaging, which ultimately led to revision surgery due to persistent 380 
shunting. Most of these dogs had clinical signs attributable to persistent shunting but a 381 
small number were apparently normal, although had markedly abnormal bile acid results.  382 
In conclusion, AC and TFB produced favorable ultimate long-term outcomes based on an 383 
owner-directed outcome measure in the reported population of dogs. However, in nearly 384 
a third of dogs treated with TFB, revision surgery was required to achieve a favorable 385 
outcome, indicating an initial therapeutic failure of the TFB in those dogs. The AC seems 386 
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Table 1. Clinical findings, management and outcomes of dogs that underwent revision 492 
surgeries, excluding one dog that had their AC revised in the immediate postoperative 493 
period. The dog that underwent two repeat surgeries is highlighted. Follow-up grades: 494 
excellent – clinically normal dogs not receiving any treatment for CPSS; good – 495 
clinically normal dogs receiving a specific diet or medication for CPSS; poor – dogs with 496 
clinical signs of CPSS or dogs that died or were euthanatized due to the CPSS (deaths are 497 
additionally explained). AC – ameroid constrictor, AUS – abdominal ultrasound, CPSS – 498 
congenital portosystemic shunt, CT – computed tomography, HE – hepatic 499 
encephalopathy, PPBA – post prandial bile acids, RV referring veterinarian, SBA – 500 























Method of attenuation at 
revision surgery 
Ultimate outcome – 
grade4 (time when 
obtained in months after 






Clinical signs and medical management at long-term follow up 
1 TFB Recurrence of clinical 
signs (HE) and persistently 
elevated SBA 
5 CT Persistent shunting poor Further partial occlusion of 
TFB by placing additional 
vascular clips 
excellent (50) 0 Clinically normal 
2 TFB Lethargy, persistently 
elevated SBA 
4 CT Persistent shunting good AC poor (50) 4 Monthly diarrhea, weekly dysuria (does not appear in discomfort) 
3 TFB Lethargy, persistently 
elevated SBA 
6 CT Persistent shunting good AC excellent (51) 0 Clinically normal 
4 TFB Behavioral changes, 
elevated SBA, owner finds 
difficult medicating 
8 CT Persistent shunting poor Full ligation poor (80) 13 Less than once monthly head pressing, circling, aggression, weakness, 
diarrhea. Retarded growth. 
5 TFB PU/PD, elevated SBA 
(were normal on 3m follow 
up) 
64 CT Shunt re-canalization good Full ligation poor (82) 6 Monthly vomiting. Retarded growth. 
6 TFB Elevated SBA found at RV 
on pre-sedation bloods for 
lameness investigation, 
mild clinical signs (more 
vocal, restless) 




Full ligation good (2) N/A N/A 
7 TFB Collapse episode, 





Recurrent signs of 
hepatic encephalopathy 
(no evidence of shunting 
seen on intraop. 
portovenography normal 
intrahepatic portal 
vasculature, liver also 
grossly normal) 
poor Full ligation good (89) 19 Less than once monthly head pressing, disorientation, ataxia, aggression, 
weakness, vomiting. Monthly circling. 
Retarded growth. Antibiotics and hepatic diet. 
8 TFB Elevated SBA 3 AUS persistent shunting good Full ligation excellent (78) 0 Clinically normal 
9 TFB Elevated SBA 3 AUS Persistent shunting good Full ligation excellent (72) 0 Clinically normal 
10 TFB Elevated SBA 4 AUS Persistent shunting good Full ligation poor (72) 6 Less than once monthly vomiting and diarrhea, monthly unresponsive 
episodes. 
11 AC Elevated SBA, urolithiasis, 
UTI 
6 AUS – shunt 
not 
confirmed 
Urolithiasis good Full ligation good (12)  N/A 
11 TFB Elevated SBA 50 CT Persistent shunting good AC good (6) N/A 
12 TFB Elevated SBA 4 CT Persistent shunting good Additional TFB placement poor – death in hospital  2 
days post surgery – possible 
portal thrombus. 
N/A - 
13 TFB Elevated SBA 6 CT Persistent shunting good AC poor – death/euthanasia due 
to CPSS 
54 Weekly circling, daily seizures, head pressing, disorientation, aggression, 
unresponsive episodes. Antibiotics, lactulose, hepatic diet. 




Elevated SBA (persistent 
shunting) 




Table 2. Long-term outcomes for dogs treated for extrahepatic congenital portosystemic 503 
shunts by thin film banding (TFB) and ameroid constrictor (AC). Dogs that had revision 504 
surgery (n=14) were excluded from this table – outcomes for those dogs are reported 505 
separately in Table 1. Information was available for 41 dogs. 506 
 TFB (n=26) AC (n=15) Total (n=41) 
Median time of follow 
up in months (range) 
66.5 (15-88) 48 (26-72) 53 (15-88) 
Follow up available 
for 
26/35 (74%) 15/22 (68%) 41 
Dogs alive 24 (92%) 14 (93%) 38 (93%) 
Dogs dead or 
euthanized due to 
CPSS 
2 (8%) 0 2 (5%) 
Dogs dead or 
euthanized unrelated 
to CPSS 
0 1 (7%) 1 (2%) 
Excellent outcome4 16 (62%) 7 (47%) 23 (56%) 
Good outcome4 0 3 (20%) 3 (7%) 
Poor outcome4 10 (38%) 5 (33%) 15 (37%) 
Median CPSS score 
(range)21  




Table 3. Outcomes, congenital portosystemic shunt (CPSS) scores and quality of life 508 
scores for 27 dogs treated for CPSS by thin film banding and ameroid constrictor. Dogs 509 
who had revision surgery are included. 510 
Short term follow up 
grade4 
Long term follow 
up grade4  
CPSS score21 / 110 Owner reported 
Quality of life score / 
100  
1 1 0 99 
2 1 0 100 
2 1 0 90 
2 3 16 96 
2 1 0 100 
2 3 3 100 
2 1 2 96 
2 1 6 94 
2 3 16 75 
2 3 20 100 
n/a 1 4 92 
2 3 4 70 
3 3 13 79 
2 3 6 90 
2 3 3 100 
1 1 4 76 
2 1 0 100 
n/a 1 4 95 
2 3 19 88 
n/a 1 0 100 
n/a 1 0 100 
2 2 0 99 
2 3 11 99 
2 1 4 100 
2 1 4 100 
2 1 0 100 
1 1 0 100 
 511 
